Quantitatively Evaluate the Improvement of Functional Cure for the Quality of Life of Chronic Hepatitis B Cases: Evidence from a Cross-Sectional Study in China
Open Access
- 14 October 2025
- journal article
- research article
- Published by MDPI AG in Healthcare
- Vol. 13 (20) , 2590
Abstract
Background: Functional cure of chronic hepatitis B (CHB) can be achieved with appropriate antiviral treatment. However, few studies have evaluated the added benefits of achieving functional cure. We aimed to conduct a quantitative analysis of the health-related quality of life (HRQoL) of CHB patients who achieved functional cure to provide evidence for economic analysis. Methods: We conducted a cross-sectional study in five provinces in China in 2021. The study population was recruited in hospitals and divided into three groups: functional cure, antiviral treatment, and healthy control group. Data were collected through face-to-face interviews using the Short Form-36 version 2. Results: 497 participants (163 with functional cure, 192 with antiviral treatment, and 142 with healthy control) were used in this study. The eight scale scores (physical function, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health) and two summary scores (physical composite and mental composite) in the functional cure and healthy control groups were similar. Compared to the healthy control group, the general health scores in the functional cure group were worse with −0.052 (95% CI: −0.094, −0.010), and the antiviral treatment group had significantly worse scores with −0.127 (95% CI: −0.170, −0.083). The antiviral treatment group had lower vitality scores (β = −0.048, 95% CI: −0.089 to −0.007) and MCS scores (β = −0.023, 95% CI: −0.042, −0.003, p = 0.022) compared to the healthy control. The mental composite summary scores of all groups were >50 (p > 0.05). Conclusions: Health-related quality of life decreases with CHB disease progression. The results indicate that functional cure is associated with HRQoL levels comparable to those of the healthy population, both on the physical and psychological aspect, reinforcing the clinical value of this therapeutic goal.Keywords
Funding Information
- The Chinese Foundation for Hepatitis Prevention and Control (CFHPC079)
This publication has 32 references indexed in Scilit:
- Quality of life in patients with HBV infection: A systematic review and meta-analysisJHEP Reports, 2025
- New progress in HBV control and the cascade of health care for people living with HBV in China: evidence from the fourth national serological survey, 2020The Lancet Regional Health - Western Pacific, 2024
- Cost-effectiveness of expanded antiviral treatment for chronic hepatitis B virus infection in China: an economic evaluationThe Lancet Regional Health - Western Pacific, 2023
- Health-related quality of life improves after entecavir treatment in patients with compensated HBV cirrhosisHepatology International, 2021
- Quality of life and unmet needs in patients with chronic liver disease: A mixed-method systematic reviewJHEP Reports, 2021
- Social stigmatization in Turkish patients with chronic hepatitis B and CGastroenterología y Hepatología, 2021
- Global liver disease burdens and research trends: Analysis from a Chinese perspectiveJournal of Hepatology, 2019
- HBsAg seroclearance further reduces hepatocellular carcinoma risk after complete viral suppression with nucleos(t)ide analoguesJournal of Hepatology, 2019
- Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling studyThe Lancet Gastroenterology & Hepatology, 2018
- Hepatitis B cure: From discovery to regulatory approvalJournal of Hepatology, 2017